Navigation auf zora.uzh.ch

Search ZORA

ZORA (Zurich Open Repository and Archive)

Migration von ZORA auf die Software DSpace

ZORA will change to a new software on 8th September 2025. Please note: deadline for new submissions is 21th July 2025!

Information & dates for training courses can be found here: Information on Software Migration.

Mobilization of hematopoietic progenitor cells with standard or reduced dose filgrastim after vinorelbine in multiple myeloma patients. a randomized prospective single center phase II study

Samaras, Panagiotis; Rütti, Markus F; Seifert, Burkhardt; Bachmann, Helga; Schanz, Urs; Eisenring, Maya; Renner, Christoph; Müller, Antonia Maria Susanne; Schmidt, Adrian; Mischo, Axel; Fuchs, Ivo; Bargetzi, Mario; Manz, Markus G; Stupp, Roger; Petrausch, Ulf; Stenner-Liewen, Frank (2018). Mobilization of hematopoietic progenitor cells with standard or reduced dose filgrastim after vinorelbine in multiple myeloma patients. a randomized prospective single center phase II study. Biology of Blood and Marrow Transplantation, 24(4):694-699.

Abstract

Vinorelbine combined with filgrastim (r-metHuG-CSF) at a dose of 10 µg/kg of body weight (BW) per day is a reliable and well tolerated regimen for mobilization of hematopoietic progenitor cells (HPC) in patients with multiple myeloma. This prospective randomized phase 2 study was initiated to assess the feasibility of a reduced filgrastim dosage. Vinorelbine was combined with either standard dosed filgrastim (10 µg/kg body weight (BW) per day) or reduced dosed filgrastim (5 µg/kg BW per day). Leukapheresis sessions were planned to start at day 8 and were continued until the predefined target amount of 4 x 106 HPC/kg BW was collected. The study demonstrated the feasibility of vinorelbine combined with reduced daily filgrastim with a mean of 1.29 leukapheresis sessions necessary per patient (95% confidence interval 0.95-1.7). All patients could start leukapheresis as planned at day 8, and the collection success rate was 100% for the whole patient collective after a maximum of two leukapheresis sessions. No statistically significant differences with regard to the amount of HPC collected between the two groups were observed (p=0.99). Accordingly, no differences were seen with regard to length of hospitalization for autotransplant (p=0.34), duration of neutrophil (p=0.93) and platelet engraftment (p=0.42). Patients receiving reduced dose filgrastim reported significantly lower peak pain values in a numerical analogue scale (p=0.01), and the costs were significantly lower than in the patients undergoing standard dosed chemo-mobilization (p=0.001). Vinorelbine 35 mg/m2 plus filgrastim 5 µg /kg BW once per day until completion of HPC collection is feasible and appears to be advantageous with respect to the severity of pain intensity and treatment costs.

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Oncology and Hematology
04 Faculty of Medicine > University Hospital Zurich > Clinic for Immunology
04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Hematology
Health Sciences > Transplantation
Language:English
Date:2018
Deposited On:08 Jan 2018 20:18
Last Modified:17 Jul 2025 01:37
Publisher:Elsevier
ISSN:1083-8791
OA Status:Closed
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1016/j.bbmt.2017.12.775
PubMed ID:29246820
Full text not available from this repository.

Metadata Export

Statistics

Citations

Dimensions.ai Metrics
3 citations in Web of Science®
5 citations in Scopus®
Google Scholar™

Altmetrics

Authors, Affiliations, Collaborations

Similar Publications